The Sanofi Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent directors
Paris, February 22, 2024
. During its meeting of February 22, 2024, the Board of Directors of Sanofi decided to propose, as part of the next General Meeting of Shareholders scheduled for April 30, 2024, the renewal of the mandates of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent directors.
Diane Souza, member of the Audit Committee and the Compensation Committee, and Thomas Südhof, Chairman of the Scientific Committee, are leaving the Board of Directors at the end of their second terms. The President warmly thanked them for their valuable contribution to the Board of Directors and the specialized committees to which they belonged during their mandates.
The Chairman specified that in order to best prepare for the end, in 2025, of the mandate as director of Fabienne Lecorvaisier, Chairman of the Audit Committee, the Board of Directors will be temporarily composed of 17 members from the General Meeting. general meeting of shareholders of April 30, 2024.
Clotilde Delbos
is currently a director of Axa and Alstom. She held various positions in internal audit, mergers and acquisitions and treasury, in California, Brussels and France, notably at Price Waterhouse and within the Pechiney group, before becoming Divisional Financial Director. In 2012, she joined the Renault group. In 2016, Clotilde Delbos was appointed Group Financial Director and Chairman of the Board of Directors of RCI Banque SA. She was then appointed interim Managing Director of Renault SA, Deputy Managing Director of the group and Managing Director of
Mobilize
. Clotilde Delbos was elevated to the rank of Knight of the Legion of Honor in 2021.
Clotilde Delbos graduated from EM Lyon with a specialization in accounting.
Anne-Françoise Nesmes
is currently Chief Financial Officer of Smith + Nephew PLC, a role from which she will resign at the end of the first quarter of 2024. She joined the Board of Compass Group PLC as a director in 2018 and is currently an independent director, Chair of the Committee and member of the Corporate Responsibility, Nomination and Remuneration Committee. She held several finance positions within international companies before joining GlaxoSmithKline PLC in 1997 where she worked for 16 years, including as Senior Vice President of Vaccine Finance. She was then appointed Chief Financial Officer of Dechra Pharmaceuticals PLC and Merlin Entertainments PLC (2013-2020).
Anne-Françoise Nesmes holds a Master’s degree from the Grenoble Ecole Supérieure de Commerce and a Master’s degree in
Business Administration
from Henley Business School. She also obtained a certification in management accounting (Chartered Management Accountant).
John Sundy
is currently Chief Medical Officer and Head of Research and Development at Seismic Therapeutic, an immunology machine learning company, and Assistant Professor of Medicine in the Division of Rheumatology and Immunology at the University of Duke in the United States. He was a tenured faculty member at Duke University before joining the biotechnology industry in 2014. Between 2014 and 2021, he held several leadership positions, including Senior Vice President at Gilead Sciences and Medical Director at Pandion Therapeutics.
He is also a director of Neutrolis, Inc. and the
Childhood Arthritis and Rheumatology Research Alliance
and sits on
Steering Committee
of
NIH Immune Tolerance Network
.
John Sundy received his bachelor’s degree in biology from Bucknell University and his doctorate in medicine from Hahnemann University with a specialization in immunology, and completed clinical training in rheumatology and allergy/immunology at Duke.
Frédéric Oudéa
Chairman of the Board of Directors
“The arrivals of Clotilde Delbos, Anne-Francoise Nesmes and John Sundy will strengthen the skills of the Board of Directors in financial and scientific matters, particularly in the field of immunology. I would like to pay tribute to the remarkable contribution of Diane Souza and Thomas Südhof to the work of the Council, and am pleased that the Council can continue to diversify its profiles and expertise in line with the group’s strategic developments. »
The composition of the specialized committees of the Board will be reviewed following the General Meeting of Shareholders scheduled for April 30, 2024.
About Sanofi
We are an innovative, global health company driven by a purpose: pursuing the miracles of science to improve people’s lives. Our teams, present in around a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Nicolas Obrist
| + 33 6 77 21 27 55 | [email protected]
Victor Rouault
| + 33 6 70 93 71 40 |
Investor relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| +1 908 612 7239 | [email protected]
Tarik Elgoutni|
+1 617 710 3587 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Attachment